Effect of surgical experience on results of esophagectomy for esophageal carcinoma

Miller, Jordan; Jain, Mukul; Gara, C. J. de; Morgan, Douglas; Urschel, John D.

doi:10.1002/(sici)1096-9098(199705)65:1<20::aid-jso4>3.0.co;2-q

Cited by 120 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we consider this ®gure acceptable. Radical esophagectomy is a complex operation, and the surgeon's experience correlates closely with outcome [14]. Furthermore, it is reasonable to expect that improvements in technique and instrumentation will occur as worldwide experience grows.…”

Section: Discussionmentioning

confidence: 99%

Video-assisted thoracoscopic esophagectomy and radical lymph node dissection for esophageal cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Video-assisted thoracoscopic esophagectomy and radical lymph node dissection for esophageal cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…A large number of reports about genetic changes in ESCC have already been published, but little is known about the major tumor suppressor genes or major oncogenes in the process of tumor progression of this malignant disease. ESCC is still a fatal malignancy with a 5-year rate of 5% to 20% for advanced stage patients undergoing a curative resection (3). This miserable prognosis for ESCC involves not only the aggressive character of this tumor but also the limited number of useful markers available for diagnostic purposes.…”

Section: Introductionmentioning

confidence: 99%

Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients

Hoshino¹,

Matsubara²,

Akutsu³

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. Peroxiredoxins (Prdxs) are a family of antioxidant enzymes that are also known as scavengers of peroxide in mammalian cells. Some reports have shown that the overexpression of Prdx1, which is one of the peroxiredoxins that is a ubiquitously expressed protein, was related to a poor prognosis in several types of human cancers. In this study, we investigated the expression levels of Prdx1 in esophageal squamous cell carcinoma by immunohistochemistry, and the correlation between the Prdx1 expression and the clinical status was elucidated. Immunohistochemical staining was performed in 114 samples which were collected from surgical esophageal cancer specimens. Cytoplasmic staining of Prdx1 was evaluated based on the following scoring criteria: Grade I, negative or weak staining; Grade II, moderate staining; and Grade III, strong staining. The percentage of patients with a Grade I expression of Prx1 was 20% (23 of 114), 44% had Grade II (50 of 114), and 36% had Grade III (41 of 114). The Prdx1 immunoreactivity showed an inverse significant correlation with T-category (P<0.0001), lymph node metastasis (P=0.048), and stage (P=0.001). In addition, the patients with tumors exhibiting a reduced Prdx1 expression had shorter overall survival (P=0.022) in comparison to the patients with tumors which had a higher Prdx1 expression. Currently, Prdx1 has been shown to act as a tumor suppressor. Our results provide strong evidence that the reduced Prdx1 expression is an important factor in esophageal squamous cancer progression and could serve as a useful prognostic marker. IntroductionEsophageal cancer is the eighth most frequent cancer and the sixth most frequent cause of death from malignant disease in the world (1). Esophageal squamous cell carcinoma (ESCC) is the most common type in Japan (2). A large number of reports about genetic changes in ESCC have already been published, but little is known about the major tumor suppressor genes or major oncogenes in the process of tumor progression of this malignant disease. ESCC is still a fatal malignancy with a 5-year rate of 5% to 20% for advanced stage patients undergoing a curative resection (3). This miserable prognosis for ESCC involves not only the aggressive character of this tumor but also the limited number of useful markers available for diagnostic purposes.Therefore, better markers which indicate the malignant potential of ESCC should help in the prognosis or optimal treatment of the patients suffering from this disease. In this study, we focus on Prdx1, one of the peroxiredoxins (Prdxs) belonging to a novel antioxidant family, which has been reported to be a tumor suppressor gene. Prdx1 has been thought to have an inhibitory function for both c-Abl and c-Myc, of which active forms cause several neoplasms (4,5). Neumann et al (6) showed, using Prdx1 knockout mice, that Prdx1 expression correlated with the reactive oxygen species and the incidence of malignant disease. Moreover, our previous study using a cDNA microarray showed that one of the novel histone deacet...

show abstract

“…Esophageal squamous cell carcinoma is a highly malignant disease with poor prognosis, the overall 5-year survival rate being only in a range of 5% to 25% (1,2). Recently, applications of combined chemotherapy and radiotherapy, or the combination therapy as an adjunct to surgery, have improved the prognosis of esophageal squamous cell carcinoma patients (3,4).…”

mentioning

confidence: 99%

Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells

Hoshino

Matsubara

Hanari

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The histone deacetylase inhibitor FK228 shows strong activity as a potent antitumor drug but its precise mechanism is still obscure. The purpose of this study is to reveal the effect of FK228 on gene expression in the cell and to determine the mechanism of the antitumor activity of FK228 for further clinical applications. Experimental Design and Results: Microarray analysis was applied to verify the gene expression profiles of 4,608 genes after FK228 treatment using human esophageal squamous cell cancer cell lines T.Tn and TE2. Among them, peroxiredoxin 1 (Prdx1), a member of the peroxiredoxin family of antioxidant enzymes having cell growth suppression activity, as well as p21 WAF1 , were significantly activated by FK288. In addition, FK228 strongly inhibited the cell growth of T.Tn and TE2 by the induction of apoptosis. Further, chromatin immunoprecipitation analysis revealed that FK228 induced the accumulation of acetylated histones H3 and H4 in Prdx1 promoter, including the Sp1-binding site. In mouse xenograft models of T.Tn and TE2 cells, FK228 injection resulted in significant tumor regression as well as activated Prdx1 expression in tumor tissues. Prdx1 suppression by RNA interference hindered the antitumor effect of FK228. Conclusion: Our results indicate that the antitumor effect of FK228 in esophageal cancer cells is shown at least in part through Prdx1 activation by modulating acetylation of histones in the promoter, resulting in tumor growth inhibition with apoptosis induction.

show abstract

Effect of surgical experience on results of esophagectomy for esophageal carcinoma

Cited by 120 publications

References 10 publications

Video-assisted thoracoscopic esophagectomy and radical lymph node dissection for esophageal cancer

Video-assisted thoracoscopic esophagectomy and radical lymph node dissection for esophageal cancer

Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients

Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells

Contact Info

Product

Resources

About